These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30609008)

  • 21. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ixekizumab (Taltz)--a second IL-17A inhibitor for psoriasis.
    Med Lett Drugs Ther; 2016 May; 58(1494):59-60. PubMed ID: 27148922
    [No Abstract]   [Full Text] [Related]  

  • 23. A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis.
    Peranteau AJ; Turkeltaub AE; Tong Y; Nawas Z; Tyring SK
    Skin Therapy Lett; 2016 Nov; 21(6):1-6. PubMed ID: 27825174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis.
    Azevedo A; Torres T
    Actas Dermosifiliogr; 2017 May; 108(4):305-314. PubMed ID: 27887675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period.
    Megna M; Cinelli E; Balato A; Gallo L; Fabbrocini G
    J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):e152-e153. PubMed ID: 31715054
    [No Abstract]   [Full Text] [Related]  

  • 27. The safety of ixekizumab in psoriasis drug therapy.
    Puig L
    Expert Opin Drug Saf; 2020 Feb; 19(2):117-130. PubMed ID: 31874129
    [No Abstract]   [Full Text] [Related]  

  • 28. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
    Leonardi C; Matheson R; Zachariae C; Cameron G; Li L; Edson-Heredia E; Braun D; Banerjee S
    N Engl J Med; 2012 Mar; 366(13):1190-9. PubMed ID: 22455413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Injection site reactions to ixekizumab - a series of four patients.
    NicDhonncha E; Bennett M; Murphy LA; Murphy M; Bourke JF
    Int J Dermatol; 2020 May; 59(5):e137-e139. PubMed ID: 31975499
    [No Abstract]   [Full Text] [Related]  

  • 30. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
    Strober B; Leonardi C; Papp KA; Mrowietz U; Ohtsuki M; Bissonnette R; Ferris LK; Paul C; Lebwohl M; Braun DK; Mallbris L; Wilhelm S; Xu W; Ljungberg A; Acharya N; Reich K
    J Am Acad Dermatol; 2017 Mar; 76(3):432-440.e17. PubMed ID: 27889292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of IL-17 inhibitors for psoriasis.
    Amin M; Darji K; No DJ; Bhutani T; Wu JJ
    J Dermatolog Treat; 2018 Jun; 29(4):347-352. PubMed ID: 29058501
    [No Abstract]   [Full Text] [Related]  

  • 32. Anemia in a psoriatic patient treated with ixekizumab.
    Nieto-Benito LM; Mateos-Mayo A; Romero-Jiménez R; Baniandrés-Rodríguez O
    J Dermatol; 2020 May; 47(5):e209-e210. PubMed ID: 32124479
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.
    Lebwohl MG; Blauvelt A; Menter A; Papp KA; Guenthner S; Pillai R; Israel RJ; Jacobson A
    Am J Clin Dermatol; 2019 Dec; 20(6):863-871. PubMed ID: 31493163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
    Sherman S; Solomon Cohen E; Amitay-Laish I; Hodak E; Pavlovsky L
    Acta Derm Venereol; 2019 Jul; 99(9):769-773. PubMed ID: 31017250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis treated with ixekizumab from 16 clinical studies.
    Blauvelt A; Ramharter M; Cohen AD; Xu W; Patel H; Schuster C; Riedl E; Puig L
    J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):e828-e831. PubMed ID: 34310771
    [No Abstract]   [Full Text] [Related]  

  • 36. Ixekizumab treatment for drug-induced erythrodermic psoriasis.
    Pinto-Pulido EL; Polo-Rodríguez I; González-Cañete M; García-Verdú E; Piteiro-Bermejo AB; Medina-Montalvo S
    Dermatol Ther; 2022 Nov; 35(11):e15863. PubMed ID: 36175131
    [No Abstract]   [Full Text] [Related]  

  • 37. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
    Medina-Gil C; Dehesa L; Vega A; Kerdel F
    Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
    Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
    J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Broadalumab (Siliq)--another IL-17A antagonist for psoriasis.
    Med Lett Drugs Ther; 2017 Jul; 59(1525):118-119. PubMed ID: 28699932
    [No Abstract]   [Full Text] [Related]  

  • 40. Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.
    Dennehy EB; Zhang L; Amato D; Goldblum O; Rich P
    J Drugs Dermatol; 2016 Aug; 15(8):958-61. PubMed ID: 27537996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.